Company presentation for investors

2014 Q1



Forward-looking statements

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forwardlooking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.



Contents

- 4 Results 2014 Q1 and Outlook
- **11** Strategy and financial targets
- 15 Orion R&D long term opportunities
- 33 Proprietary Products andSpecialty Products update
- 41 Key financials
- 48 General info





Results 2014 Q1 & Outlook



First marketing authorisations in Europe for Bufomix Easyhaler®

- Net sales similar to comparative period
- Operating profit slightly lower than in previous year as anticipated
- Bufomix Easyhaler[®] gained first marketing authorisations in Europe
- Generic competition to Precedex not yet started in USA
- First marketing authorisations for generic competitors to Stalevo granted in Germany
- Capital expenditure programme proceeding: first packaging line operational at Salo plant



Key figures for 2014 Q1

	2014 Q1	2013 Q1	Change %	2013
Net sales, EUR million	245.0	249.4	-1.8%	1 006.9
	67.4	74.1	-9.1%	267.7
Operating profit, EUR million		77.1	- 7.1/0	207.7
% of net sales	27.5%	29.7 %		26.6%
R&D expenses, EUR million	26.3	24.6	+6.8%	101.9
% of net sales	10.7%	9.9 %		10.1%
Basic earnings per share, EUR	0.37	0.39	-5.1%	1.46
Cash flow per share before financial items, EUR	0.30	0.07	+319.4%	1.02




Key figures by business areas

Key figures for Pharmaceuticals business	2014 Q1	2013 Q1	Change %	2013
Net sales of Pharmaceuticals, EUR million	229.5	234.2	-2.0%	953.0
Proprietary Products	88.2	100.3	-12.1%	390.4
Specialty Products	102.1	95.7	+6.7%	384.9
Animal Health	15.4	14.8	+4.4%	70.8
Fermion	14.9	13.4	+11.3%	63.5
Contract manufacturing and other ¹⁾	8.9	10.1	-11.7%	43.3
Pharmaceuticals operating profit, EUR million	66.7	73.9	- 9.7 %	272.9
Key figures for Diagnostics business				
Net sales, EUR million	16.3	15.9	+2.8%	57.1
Operating profit, EUR million	2.6	2.3	+14.0%	4.6


¹⁾ Contract manufacturing and other is included in the Pharmaceuticals business segment but is not a separate business division. It is part of the Group's Supply Chain organisation.



Net sales originate mainly in Europe Breakdown of EUR 245 million net sales in 2014 Q1



By market area



Building well-being

Best-selling pharmaceuticals

Orion's best-selling pharmaceuticals, EUR million	Business Division	Q1/2014	Q1/2013	Change %	2013
1. Stalevo®, Comtess® and Comtan® (Parkinson's disease)	PP	47.2	60.3	-22%	207
2. Simdax [®] (acute decompensated heart failure)	PP	10.7	10.8	-2%	46
3. Precedex [®] (intensive care sedative)	PP	9.0	12.0	-25%	59
4. dexdor [®] (intensive care sedative)	PP	8.0	5.7	+40%	25
5. Easyhaler® product family (asthma, COPD)	PP	7.8	6.2	+27%	29
6. Generic entacapone products (Parkinson's disease)	SpP	6.8	2.6	+165%	10
7. Burana® (inflammatory pain)	SpP	5.5	5.8	-5%	23
8. Marevan® (anticoagulant)	SpP	4.9	4.0	+21%	16
9. Dexdomitor [®] , Domitor [®] , Domosedan [®] and Antisedan [®] (animal sedatives)	АН	4.9	4.9	-1%	25
10. Trexan [®] (rheumatoid arthritis, cancer)	SpP	3.4	2.9	+15%	11
Total		108.1	115.2	-6%	452
Share of Pharmaceuticals net sales		47%	49 %		47 %

Products based on Orion's inventions in blue

PP = Proprietary Products SpP = Specialty Products AH = Animal Health



Outlook for 2014


- Net sales will be at similar level to 2013 (net sales in 2013 were EUR 1,007 million)
- **Operating profit** will be slightly lower than in 2013 (operating profit in 2013 was EUR 268 million)
- Group's capital expenditure will be about EUR 60 million excluding substantial corporate or product acquisitions (Group's capital expenditure in 2013 was EUR 78 million)



Orion's strategy and financial targets




Profitable growth and increased shareholder value whilst keeping business risks under control





Balancing mid-term – building long-term






Orion's financial objectives

Orion's financial objectives are:

- Ensuring financial stability
- Profitable growth

The objectives are achieved through:


- Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio.
- Maintaining profitability at a good level, the aim being operating profit that exceeds 20% of net sales.
- Keeping the equity ratio at least 50%.





Operating profit

Equity ratio and interest-bearing liabilities





Orion R&D long term opportunities




Orion's R&D strategy

Increased productivity	R&D operational model renewed in 2009
Focused therapy areas	Focus on three core therapy areas + generics • Central nervous system diseases • Oncology and critical care • Easyhaler pulmonary drugs
Shared risks and rewards	 Emphasis on collaboration and partnerships Clinical studies are performed globally, Orion's focus on Europe Partnerships are usually sought for clinical phase III at the latest Partners are important in marketing authorisation cases in countries outside Europe Orion holds the rights for further develop and market the candidate compounds
Focus on strengths	 In-house R&D covers mainly late-stage research and early-stage development phases i.e. discovery, preclinical phase and clinical phases I and II
Diversification	 Constant strive to Increase the overall number of programmes Balance the risks of individual projects Acquire new early research molecules Improve the life-cycle management of own innovative treatments
M&As	Active in in-licensing of drug candidates or products



Collaborative networks across the R&D value chain



Building well-being

Key clinical pharmaceutical development projects

Project	Indication	PHASE			Registration
Easyhaler [®] budesonide-formoterol	Asthma, COPD				Registration
Stalevo [®] for Japanese markets ¹⁾	Parkinson's disease	I			Registration
Easyhaler [®] salmeterol-fluticasone	Asthma, COPD		Ш	Ш	
ORM-12741 (alpha-2c adrenoceptor antagonist) ²⁾	Alzheimer's disease	I	lla		
ODM-201 (androgen receptor inhibitor)	Prostate cancer		Ш		
Levosimendan ³⁾	Low Cardiac Output Syndrome	I	Ш		
ODM-103 (more effective COMT inhibitor)	Parkinson's disease	I			
ODM-104 (more effective COMT inhibitor)	Parkinson's disease	I			
¹⁾ Partner: Novartis			= Phas	e comp	leted
²⁾ In collaboration with Janssen Pharmaceuticals			= Phase ongoing		

³⁾ Partner: Oxygen Biotherapeutics, Inc. is preparing to commence Phase III



Research projects 2013 (16)

HIT Finding	Active-To-Hit	Hit-To-Lead	Lead Optimization		
0 0	:			0 0	
Oncology A		0 0	• • • • • • • • • • • • • • • • • • •	•	
Oncology B					
Oncology C					
Oncology D					
CNS A					
CNS B	•	•			•
CNS C				•	•
CNS D					•
CNS E				0 0 0	•
CNS F				•	•
CNS G		•	• • • • • • • • • • • • • • • • • • •		•
CNS H		0 0 0	0 0 0 0 0 0 0 0	0 0 0	•
CNS I		0 0 0	0 0 0 0 0 0 0 0	0 0 0	•
CNS J		0 0 0		0 0 0	•
CNS H Super ge	eneric	•		•	•
	Biologic) for new indic	ation			•
Snapshot of Ori	on's preclinical pipeli Day on 20 November	ne presented at Orior	Precandidate ו	Candidate	СТА
·	-				
0 lauratas Des	2014.01				SRIC

DN

Building well-being

ORM-12741, alpha-2c adrenoceptor antagonist



ORM-12741 - collaboration with Janssen

- Licence agreement announced on 19 December 2013 (includes ORM-12741 and other compounds)
- Orion received USD 31 million upfront payment which will mainly be used against additional Phase IIa study costs
- Orion is eligible to receive milestone payments from Janssen upon successful completion of certain development and commercialization events, as well as royalties on future sales
- Orion has exclusive commercialization rights in Europe
- Janssen has worldwide exclusive license to develop ORM-12741 and an exclusive right to commercialize it outside Europe
- Orion and Janssen will co-fund the development after an additional Phase IIa study is completed successfully by Orion



ORM-12741, first Phase 2a Study in AD

- Objective
 - To evaluate safety and efficacy of ORM-12741 in treatment of cognitive and behavioral symptoms of Alzheimer's disease
- Design and Methodology
 - Randomised, double-blind, placebo-controlled, parallel-group Phase 2a study in 100 pts
 - Patients with moderately severe Alzheimer's disease (MMSE 12 21)
 - Behavioural and psychological symptoms present (NPI \geq 15)
 - All on stable dose of donepezil, rivastigmine or galantamine for at least 3 months
 - 2 dose levels of ORM-12741 and placebo for 12 weeks as an add-on therapy
- Main Endpoints
 - A battery of computerized neurocognitive tests (CDR System)
 - Pre-specified primary emphasis on composite scores for Quality of Episodic Memory, Quality of Working Memory, Speed of Memory and Power of Attention
 - Neuropsychiatric inventory (NPI)
 - Safety: AEs, vital signs, safety lab, ECG



ORM-12741 first Phase 2a Study — Conclusions

- Clear positive effects on memory measures on active treatment groups as compared to placebo
 - Clear and statistically significant positive treatment effect on Quality of Episodic Memory (*p=0.03)
 - Clear and statistically significant positive treatment effect on Quality of Memory (*p=0.013)
- Clear and statistically significant positive treatment effect on Neuropsychiatric Inventory (NPI) Caregiver Distress score (*p=0.034)
- Trend for positive treatment effect in Neuropsychiatric Inventory (NPI) total score for the low dose group (*p=0.12)
- ORM-12741 was generally well tolerated

*Main treatment effect (used doses: 30-60mg and 100-200 mg)



ORM-12741 — Next Steps

- A new formulation study followed by
- An additional Phase 2a in AD patients focusing on
 - Confirmation of the first Phase 2a results especially on NPI
 - Dosing
- Development options for Phase 3

Cognition

- Pros': Several compound shown to work, clear study designs, endpoints & regulatory path
- Cons': Old generic drugs on market, new competitors in pipeline, lower prize expectation than for the latter

Neuropsychiatric symptoms


- Pros': Huge unmet need, less competition, high value
- Cons': Endpoints & regulatory path less clear need clarification before Phase 3



ODM-201 a new generation androgen receptor (AR) inhibitor for prostate cancer




ODM-201 has a unique profile



- No brain entry
- No CYP inhibition or induction expected with therapeutic doses



In ARADES I/II study 12 wk PSA response was most pronounced in Chemo-/CYP17i naive patients



50% PSA response rate
86% at 700mg bid

100 mg bid 200 mg bid 700 mg bid

*Data truncated at +25%



Most common (>10%) adverse events in ARADES study by grade

Follow-up until week 12	N of patients (%) (N=124)				
	Grade 1-2	Grade 3	Grade 4		
Fatigue /Asthenia	30 (24%)	1 (1%)	-		
Back pain	17 (14%)	1 (1%)	-		
Constipation	16 (13%)	-	-		
Nausea	13 (10%)	1 (1%)	-		
Pain	13 (10%)	1 (1%)	-		
Decreased appetite	12 (10%)	-	-		

- No clear evidence that any observed toxicity is drug related
- No related seizures one case of convulsion was reported 27 days after stopping treatment
- Safety profile after longer treatment period remains similar



Conclusions from clinical studies and next steps

- ODM-201 is a safe and well tolerated treatment
 - Adverse events were mostly mild, and seemed to be related to prostate cancer or concomitant diseases
- High response rate in chemo/CYP17i-naïve patients
 - 700 mg bid has the best responses in chemo-/CYP17inaïve patients. High dose further supported by efficacy data of the formulation bridging study (data to be presented in 2014)

- A Phase 3 study in nmCRPC patients is scheduled to start recruitment in Q2/2014
 - Patients at high risk for developing metastasis as assessed by PSA doubling time
 - To demonstrate the efficacy of ODM-201 for delaying progression to metastatic disease
 - Over 300 sites in more than 20 countries
 - The study was discussed with EMA and FDA as part of end of phase 2 advice process
- Discussions ongoing with partner candidates about other studies (phase 2 and 3)



ODM-103 and ODM-104 for Parkinson's disease



ODM-103 and -104 for Parkinson's disease

ODM-103, more effective COMT-inhibitor

Pre-clinical study

• Pre-clinical study results indicated that ODM-103 is more effective than entacapone

Phase I Safety study ongoing in Europe since summer 2012

ODM-104, more effective COMT-inhibitor


Pre-clinical study

• Pre-clinical study results indicated that ODM-104 is more effective than entacapone

Phase I Safety study ongoing in Europe since summer 2013



Target is to develop the best possible peroral levodopa product to increase premium for market access - improved efficacy / reduced OFF-time



Building well-being

Proprietary Products and Specialty Products update



Product protection situation of key products

Key patents or data protection expire

Molecule	Product	Indication	Europe	USA	Japan
Entacapone	Stalevo [®] , Comtess [®] and Comtan [®]	Parkinson's disease	November 2012 October 2013 ¹⁾	October 2013	January 2015 ²⁾
Levosimendan	Simdax®	Acute decompensated heart failure	September 2015	Not marketed	Not marketed
Dexmedetomidine	Precedex [®] dexdor [®]	Intensive care sedative	July 2013 September 2021 ³⁾	January 2014 ⁴⁾	June 2012

¹⁾ Stalevo data protection expired


²⁾ Data protection expires; currently only Comtan available, project to develop Stalevo for Japanese markets ongoing

³⁾ Dexdor data protection expires

⁴⁾ Six months paediatric exclusivity granted for Precedex in the United States expired



Turning points of Parkinsons's franchise




Comtan in-market sales EUR 24 million in 2012, EUR 20 million in 2013 **Stalevo in-market sales** EUR 79 million in 2012, EUR 76 million in 2013

Source: IMS Health 2013




Rx value shares in USA after generic launches

Total Rx value in USA - all entacapone products






Precedex® and *dexdor*® intensive care sedatives







Easyhaler[®] for asthma and COPD



1993 Buventol Easyhaler® (salbutamol)



Easyhaler® (formoterol)



1994 Beclomet Easyhaler®

(beclomethasone)

2002 Buventol Easyhaler® (budesonide)



2010→ Development of fluticasone-salmeterol








- Easyhaler® is authorised in 30 countries and • coverage expanding, excl. USA and Japan
- Rights to Easyhaler ® products repatriated in • various European countries in 2012



Retail sales of inhaled respiratory drugs market in Top 5 Europe






39 Investor Presentation 2014 Q1

Source: IMS Health 2013


Launches are basis for future growth in SpP

Specialty Products launches



SpP launches in 2013

By geographic area						
Eastern Europe	27					
Scandinavia	37					
Finland	26					
Other	9					













Key figures by quarter











42 Investor Presentation 2014 01

Key figures for 2010–Q1/2014

Orion's key figures	2010	2011	2012	2013	Q1/2014	Q1/2013	Change %
Net sales, EUR million	849.9	917.9	980.4	1,006.9	245.0	249.4	-1.8%
Operating profit, EUR million	254.2	282.9	278.3	267.7	67.4	74.1	- 9.1 %
Profit before taxes, EUR million	252.6	282.0	276.6	264.0	66.5	73.8	-9.9%
R&D expenses, EUR million	85.5	87.5	105.8	101.9	26.3	24.6	+6.8%
Equity ratio, %	62.7%	64.2%	61.0%	53.6%	38.9%	41.2%	
Gearing, %	-12.2%	- 6.9 %	-1.7%	8.4%	-0.1%	-4.6%	
ROCE (before taxes), %	45.0%	49.4%	45.9%	38.5%	38.9%	50.6%	
Return on equity, %	40.7%	43.3%	41.0%	40.3%	46.5%	49.8%	
Basic earnings per share, EUR	1.31	1.49	1.47	1.46	0.37	0.39	-5.1%
Cash flow per share before financial items, EUR	1.26	1.10	1.23	1.02	0.30	0.07	+319.4%
Dividend per share, EUR	1.20	1.30	1.30	1.25			
Capital repayment per share, EUR	0.06	0.12					



Income Statement 2010-Q1/2014

Formation of profits, EUR million	2010	2011	2012	2013	Q1/2014	Q1/2013	Change %
Net sales	849.9	917.9	980.4	1,006.9	245.0	249.4	-1.8%
Cost of goods sold	-283.2	-305.1	-350.8	-393.5	-95.8	-91.8	+4.4%
Gross profit	566.8	612.8	629.6	613.4	149.2	157.6	-5.3%
Other operating income and expenses	1.2	3.0	6.3	5.6	0.2	0.3	- 38.9 %
Sales and marketing expenses	-188.9	-204.8	-206.1	-204.9	-46.3	-48.5	-4.6%
R&D expenses	-85.5	-87.5	-105.8	-101.9	-26.3	-24.6	+6.8%
Administrative expenses	-39.3	-40.6	-45.7	-44.5	-9.4	-10.6	-12.0%
Operating profit	254.2	282.9	278.3	267.7	67.4	74.1	- 9.1 %
Profit before taxes	252.6	282.0	276.6	264.0	66.5	73.8	- 9.9 %
Profit for the period	184.7	209.5	206.9	206.2	52.6	55.6	-5.3%




Financial position

EUR million	3/14	3/13	Change%	EUR million	3/14	3/13	Change%
Non-current assets total	354.0	334.2	+5.9%				
Inventories	198.0	189.2	+4.6%	Equity total	392.0	382.4	+2.5%
Trade receivables	168.3	164.4	+2.4%	Interest-bearing non- current liabilities	229.3	103.4	+121.6%
Other receivables	52.4	48.2	+8.8%	Non-current liabilities total	261.4	147.0	+77.8%
Cash and cash equivalents	254.3	192.7	+31.9%	Current liabilities total			
Current assets total				Liabilities total	373.5	399.4	-6.5%
	673.0	594.5	+13.2%	Equity and liabilities	634.9	546.4	+16.2%
Assets total	1,026.9	928.7	+10.6%	total	1,026.9	928.7	+10.6%




Development of Net working capital



Inventories

Short-term non-interest bearing liabilities


Net Working Capital



Building well-being

Dividend distribution policy

Orion's dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives.



Building well-being






Building well-being since 1917

Orion is an innovative, European, R&D-based, pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets

Orion in brief	2013
Net sales	EUR 1 007 million
Operating profit	EUR 268 million
R&D expenses	EUR 102 million
No. of personnel (at end of)	3,519
in Finland	2,816
in other countries	703
Market cap on 31 Mar 2014	EUR 3.1 billion





Business units



Proprietary Products

Patented prescription drugs
CTAs: CNS, oncology & critical care, Easyhaler pulmonary drugs
Net sales in 2013 EUR 390 million



Fermion

Active pharmaceutical ingredients (API's) for Orion and other companies
Net sales in 2013 EUR 64 million (excluding supplies for own use)



Specialty Products

Generic prescription drugs
Self-care products
Net sales in 2013 EUR 385 million



Contract Manufacturing & Other¹⁾

- Pharmaceutical manufacturing for other companies
 Not sales in 2012 EUP 42 million
- Net sales in 2013 EUR 43 million



Animal Health

 Veterinary medicines and care products for pets and production animals
 Net sales in 2013 EUP 71 million

• Net sales in 2013 EUR 71 million



Orion Diagnostica

 Diagnostic test systems for point-ofcare testing in healthcare and hygiene testing for industry
 Net sales in 2013 EUR 57 million

1) Contract manufacturing and other is included in the Pharmaceuticals business segment but is not a separate business division. It is part of the Group's Supply Chain organisation.



Market position strengthened in Europe

Finland Market leader

Scandinavia Strong domestic market position

Eastern Europe Generics


Western and Central Europe Strong position with proprietary products

Southern Europe Progress with proprietary products in hospital markets






Orion shares are broadly held



By number of shares on 31 Mar

By number of votes on 31 Mar



- Households
- Non-Finnish holders and nominee registered
- Private corporations
- Public sector
- Non-profit institutions
- Financial and insurance corporations

Altogether 141.3 million shares and ca. 55,500 shareholders. Both share classes, A and B, are listed on NASDAQ OMX Helsinki since 1 July 2006. A share (ORNAV) has 20 votes/share and B share (ORNBV) has 1 vote/share in the AGM, but they have equal rights to assets and dividends.




Public sector

Non-profit institutions

Financial and insurance corporations

Orion B share performance 3 July 2006–17 April 2014





Jari Karlson CFO jari.karlson@orion.fi +358 10 426 2883

Tuukka Hirvonen Communications Manager Financial Communications & Investor Relations <u>tuukka.hirvonen@orion.fi</u> +358 10 426 2721

Heidi Ahti Executive Assistant (Investor meeting requests) <u>heidi.ahti@orion.fi</u> +358 10 426 2169

www.orion.fi/EN/Investors

twitter.com/OrionCorplR

Orion Investor Relations

